Dr. Roger M. Lyons, MD
Hematology (Hematology (Internal Medicine) Physician)
At a glance
- Years since graduation
- 59
- In the NPI registry since
- 2006
Licensed in Texas since 1975, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
TX license E3811 (first issued 1975; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Protein measurement, serum | 226 | 205 |
| Immunologic analysis technique on serum (immunofixation) | 194 | 174 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $350 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $125 |
|---|---|
| Pfizer Inc. | $123 |
| Genzyme Corporation | $102 |
| Food and Beverage | $350 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $32,347 in research payments for these studies, mostly to the institutions running them.
- C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Pr…
Takeda Pharmaceuticals U.S.A., Inc. - Polarix
Genentech, Inc. - Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic …
Novartis Pharmaceuticals Corporation - A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Takeda Pharmaceuticals U.S.A., Inc. · Terminated · NCT03173092 - A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT01712490
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.